RFG Advisory LLC Takes $1.53 Million Position in Halozyme Therapeutics, Inc. $HALO

Key Points

• RFG Advisory purchased a new $1.53 million stake in Halozyme Therapeutics, acquiring 19,613 shares during the second quarter. Institutional investors collectively own 97.79% of the company.
• Halozyme reported strong quarterly results, with EPS of $2.28 and revenue of $481 million, exceeding estimates and representing 47.7% year-over-year revenue growth.
• Analyst sentiment remains positive, with the stock receiving a “Moderate Buy” consensus rating and an average price target of $91.20, while insiders sold approximately $7.37 million in shares over the past 90 days.

RFG Advisory LLC purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 19,613 shares of the biopharmaceutical company's stock, valued at approximately $1,535,000.

Other large investors have also recently bought and sold shares of the company. Measured Wealth Private Client Group LLC increased its position in Halozyme Therapeutics by 51.5% during the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 124 shares during the period. Larson Financial Group LLC boosted its holdings in Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 343 shares during the period. MidFirst Bank acquired a new position in shares of Halozyme Therapeutics during the 2nd quarter worth approximately $27,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Halozyme Therapeutics during the 2nd quarter worth approximately $28,000. Finally, Quantbot Technologies LP bought a new position in shares of Halozyme Therapeutics during the second quarter worth approximately $30,000. 97.79% of the stock is owned by institutional investors.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Mahesh Krishnan sold 7,304 shares of the firm's stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $75.00, for a total value of $547,800.00. Following the sale, the director owned 14,462 shares in the company, valued at $1,084,650. This trade represents a 33.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the company's stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $107.43, for a total transaction of $2,148,600.00. Following the transaction, the chief executive officer owned 767,780 shares of the company's stock, valued at $82,482,605.40. This trade represents a 2.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 72,478 shares of company stock worth $7,370,004 over the last 90 days. Insiders own 2.50% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on HALO shares. Benchmark reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Leerink Partners upgraded Halozyme Therapeutics from a "market perform" rating to an "outperform" rating and raised their price target for the stock from $83.00 to $110.00 in a research report on Friday, August 7th. Wells Fargo & Company raised their price target on Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an "equal weight" rating in a research report on Friday, August 7th. Citigroup reaffirmed a "market outperform" rating on shares of Halozyme Therapeutics in a research note on Friday, August 7th. Finally, Wall Street Zen raised shares of Halozyme Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 8th. Nine research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Halozyme Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $91.20.

Halozyme Therapeutics Trading Up 0.2%

Shares of HALO stock opened at $107.20 on Friday. Halozyme Therapeutics, Inc. has a fifty-two week low of $61.22 and a fifty-two week high of $111.15. The stock's fifty day moving average price is $93.73 and its two-hundred day moving average price is $76.97. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71. The company has a market cap of $12.17 billion, a PE ratio of 32.00, a P/E/G ratio of 0.41 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, topping analysts' consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The company had revenue of $481.00 million during the quarter, compared to analysts' expectations of $402.28 million. During the same quarter in the previous year, the firm earned $1.54 EPS. Halozyme Therapeutics's revenue was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Equities analysts predict that Halozyme Therapeutics, Inc. will post 8.25 EPS for the current fiscal year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of medicines. The company's primary technology is ENHANZE, which uses recombinant human hyaluronidase PH20 to facilitate the subcutaneous delivery of certain biologic and other injectable therapies that might otherwise require intravenous infusion.

Halozyme provides ENHANZE technology to pharmaceutical and biotechnology partners through licensing and collaboration agreements.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.